Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04844684
Recruiting Observational

Evaluation of Cortisol and Bile Acids Metabolism in Obese Patients

NCT04844684 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Lille
Phase
Observational
Started
2023-03-30
Last updated
2025-12-23

Condition(s) studied

Obesity

Investigational drug(s) / intervention(s)

Blood and urine collection

Blood and urine collection: Blood sampling urine collections before RYGP and 1 month and 1 year after.

Study summary

Bariatric surgery is currently the most efficient treatment for obesity. The sustained weight loss and metabolic improvement seen following Roux-en-Y gastric bypass (RYGB), is explained partly by modifications in hormones including bile acids (BA). After RYGB, an increased total BA pool and a reduction in hepatic cortisol exposure is observed. Hydroxysteroid 11-β dehydrogenase 1 (HSD11B1), steroid 5α-reductases (SRD5A), and steroid 5β-reductases, AKR1D1 (also a BA metabolizing enzyme), are three enzymes involved in the metabolism of cortisol in the liver and are known to participate in metabolic syndrome. Their activity has been shown to be decreased after RYGB. Interestingly, the mechanisms explaining the modification of hepatic cortisol exposure and the activity of theses enzymes after RYGB are unknown. In view of the few data suggesting a link between cortisol metabolism and bile acids, this work aim to study and characterize this link in a context of RYBP

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Non-menopausal women * BMI between 35 and 50 kg/m² included * Social insured * Ability to give consent Exclusion Criteria: * moderate and severe kidney insufficiency * hepatic insufficiency * known gallbladder lithiasis * history of cholecystectomy or cholecystectomy planned during the gastric bypass * history of bariatric surgery except gastric band and gastric balloon * history of type 1 * treatment interfering with the cortisol metabolism: taking oral or inhaled glucocorticoids within the last 6 months * treatment by BA as ursodeoxycholic acid, bile acids sequester, statin, fibrate stopped less than 4 weeks ago

Primary outcome measure(s)

  • Correlation between the variations of urinary cortisol metabolites and plasmatic total BA level before and after RYGB — At 1 year

Trial sites (1)

FacilityCityRegionStatus
Hôpital Huriez - Service d'endocrinologie, diabétologie, nutrition et métabolisme Lille France Recruiting

More University Hospital, Lille trials in France

Intraabdominal Hypertension and Occurrence of Microaspiration in Cirrhotics Under Mechanical Ventilation Recruiting
Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations Recruiting
Algorithm-based Management to Reduce the Recurrence of GI Bleeding and Severe Epistaxis in Von Willebrand Disease Recruiting
Lung Disease and FLNA Mutations Starting soon
Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma Active, not recruiting

Other trials for the same condition

Interventions to Remedy the Negative Effects of Obesity Stigma Recruiting
Chrono-restricted Diet and Physical Activity as a New Preventive Strategy for Sarcopenia in Postmenopausal Women With Obesity and Type 2 Diabetes Starting soon
Comparative 3-year Study of Nissen-sleeve vs. Sleeve Plus Cruroplasty in Obese Patients With Hiatal Hernia Starting soon
Identification of Factors Predictive of the Efficacy of Endoscopic Endoscopic Sleeve Gastroplasty Recruiting
Evaluation of Omentopexy on Gastro-oesophageal Reflux Following Sleeve Gastrectomy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04844684 on ClinicalTrials.gov ↗ ← All trials in France